Published in J Cardiovasc Surg (Torino) on August 01, 1994
Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res (1998) 3.20
Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene (1990) 2.97
Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst (1993) 2.66
Peripheral lung adenocarcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival. Radiology (2001) 1.82
Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res (1992) 1.72
Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res (2000) 1.64
Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene (1992) 1.63
An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol (2012) 1.63
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer (2007) 1.55
Inflammatory pseudotumor of the lung in adults: radiographic and clinicopathological analysis. Ann Thorac Surg (1989) 1.53
Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst (1993) 1.50
Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res (1999) 1.47
High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene (1992) 1.41
Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res (1996) 1.41
Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res (2001) 1.33
Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res (1990) 1.33
Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg (1998) 1.32
Polymorphism at codon 213 within the p53 gene. Oncogene (1991) 1.30
Induction of chromosomal gene mutations in Escherichia coli by direct incorporation of oxidatively damaged nucleotides. New evaluation method for mutagenesis by damaged DNA precursors in vivo. J Biol Chem (1998) 1.23
Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am J Physiol Lung Cell Mol Physiol (2000) 1.23
Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. J Immunol (1999) 1.22
Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station. J Thorac Cardiovasc Surg (2001) 1.22
Carcinosarcoma and spindle cell carcinoma of the lung. Clinicopathologic and immunohistochemical studies. J Thorac Cardiovasc Surg (1990) 1.20
Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence. Br J Cancer (2004) 1.19
Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classification. Eur Respir J (2011) 1.16
Mutations in the p53 gene in primary human breast cancers. Cancer Res (1991) 1.15
Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol (2007) 1.15
Frequent allelic imbalance suggests involvement of a tumor suppressor gene at 1p36 in the pathogenesis of human lung cancers. Genes Chromosomes Cancer (2000) 1.15
A clinicopathological study of gastric cancer with special reference to age of the patients: an analysis of 1,630 cases. World J Surg (1989) 1.13
Naive T cells can mediate delayed-type hypersensitivity response in T cell receptor transgenic mice. Eur J Immunol (1994) 1.11
Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer (1991) 1.09
Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res (1996) 1.07
K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer (1997) 1.05
Flow cytometric analysis of the heat shock protein 60 expressed on the cell surface of Helicobacter pylori. J Med Microbiol (1996) 1.05
Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer (2001) 1.04
High frequency of clonally related tumors in cases of multiple synchronous lung cancers as revealed by molecular diagnosis. Clin Cancer Res (2000) 1.04
Dietary factors and lung cancer risk in Japanese: with special reference to fish consumption and adenocarcinomas. Br J Cancer (2001) 1.03
Prevalence of diabetes mellitus in odontogenic infections and oral candidiasis: an analysis of neutrophil suppression. J Oral Pathol Med (1993) 1.03
Expression of Y box-binding protein-1 correlates with DNA topoisomerase IIalpha and proliferating cell nuclear antigen expression in lung cancer. Anticancer Res (2001) 1.02
Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clin Cancer Res (1996) 1.00
Reduced inhibition of Candida albicans adhesion by saliva from patients receiving oral cancer therapy. J Clin Microbiol (1995) 0.99
Low malignant intraductal carcinoma on the hard palate: a variant of salivary duct carcinoma? Eur J Cancer B Oral Oncol (1996) 0.98
Functional conversion of hemocyanin to phenoloxidase by horseshoe crab antimicrobial peptides. J Biol Chem (2001) 0.98
Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. Chest (1995) 0.98
Chronic expanding hematoma in the chest. J Cardiovasc Surg (Torino) (2000) 0.97
Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers. Oncogene (1998) 0.97
Malignant transformation of an intrathoracic neurofibroma in von Recklinghausen's disease. Scand Cardiovasc J (1998) 0.97
Prognostic impact of telomerase activity in non-small cell lung cancers. Ann Surg (1999) 0.96
Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. Br J Cancer (2007) 0.96
A frequent deletion of chromosome 5q21 in advanced small cell and non-small cell carcinoma of the lung. Cancer Res (1994) 0.96
Effects of epidermal growth factor on osteoblastic cells in vitro. Calcif Tissue Int (1983) 0.96
Heat-shock protein 60 homologue of Helicobacter pylori is associated with adhesion of H. pylori to human gastric epithelial cells. J Med Microbiol (1997) 0.95
Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer. Cancer Res (1999) 0.95
p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival. Ann Oncol (1995) 0.95
An immunohistochemical study of odontogenic mixed tumours. Eur J Cancer B Oral Oncol (1995) 0.95
Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese. Int Arch Occup Environ Health (1995) 0.94
p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res (1998) 0.94
Functional and structural diversities of C-reactive proteins present in horseshoe crab hemolymph plasma. Eur J Biochem (1999) 0.93
Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation. Am J Pathol (2001) 0.93
Immune response against a cross-reactive epitope on the heat shock protein 60 homologue of Helicobacter pylori. Infect Immun (2000) 0.92
A novel germline p53 splicing mutation in a pediatric patient with a second malignant neoplasm. Oncogene (1993) 0.92
Characteristic cytokines generated by keratinocytes and mononuclear infiltrates in oral lichen planus. J Invest Dermatol (1995) 0.92
Adenoid basal carcinoma of the uterine cervix: immunohistochemical study and literature review. Jpn J Clin Oncol (1997) 0.92
Unfavorable prognosis of patients with stage II non-small cell lung cancer associated with macroscopic nodal metastases. Chest (1999) 0.92
Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res (1995) 0.92
Expression of human telomerase subunit genes in primary lung cancer and its clinical significance. Ann Thorac Surg (2000) 0.91
Population-based mapping of pulmonary adenoma susceptibility 1 locus. Cancer Res (2000) 0.91
Serum cytokines, interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in oral disorders. Oral Surg Oral Med Oral Pathol (1994) 0.91
Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. Clin Cancer Res (1997) 0.90
A novel bovine lactoferrin peptide, FKCRRWQWRM, suppresses Candida cell growth and activates neutrophils. J Pept Res (2001) 0.90
Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest (1992) 0.90
Identification of a metastasis signature and the DLX4 homeobox protein as a regulator of metastasis by combined transcriptome approach. Oncogene (2007) 0.90
Surgical resection for pulmonary metastases of sweat gland carcinoma. Thorax (1994) 0.89
Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer. Ann Thorac Surg (1997) 0.89
MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. Ann Thorac Surg (1999) 0.89
Influence of aging on candidal growth and adhesion regulatory agents in saliva. J Oral Pathol Med (2001) 0.88
Surgical treatment of lung cancer in the octogenarian. Ann Thorac Surg (1994) 0.88
Relationship between early recurrence and micrometastases in the lymph nodes of patients with stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg (1997) 0.87
Pleural retraction and intra-tumoral air-bronchogram as prognostic factors for stage I pulmonary adenocarcinoma following complete resection. Int Surg (2001) 0.87
Increased levels of serum intercellular adhesion molecule-1 (ICAM-1) in patients with non-small cell lung cancer. Surg Oncol (1996) 0.87
Adenovirus-mediated gene therapy specific for small cell lung cancer cells using a Myc-Max binding motif. Int J Cancer (2001) 0.87
p53 mutations in non-small-cell lung cancers occurring in individuals without a past history of active smoking. Br J Cancer (1998) 0.87
Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients. Eur J Cancer (1999) 0.87
Colony formation by Helicobacter pylori after long-term incubation under anaerobic conditions. FEMS Microbiol Lett (1999) 0.87
Treatment strategy for patients with surgically discovered N2 stage IIIA non-small cell lung cancer. Ann Thorac Surg (1997) 0.87
Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer. Lung Cancer (1998) 0.86
Growth inhibition of Helicobacter pylori by monoclonal antibody to heat-shock protein 60. Microbiol Immunol (1997) 0.86
Studies of the effect of Clostridium butyricum on Helicobacter pylori in several test models including gnotobiotic mice. J Med Microbiol (2000) 0.86
Increase of Candida cell virulence by anticancer drugs and irradiation. Oral Microbiol Immunol (2001) 0.86
Mn-SOD antisense upregulates in vivo apoptosis of squamous cell carcinoma cells by anticancer drugs and gamma-rays regulating expression of the BCL-2 family proteins, COX-2 and p21. Int J Cancer (2001) 0.86
Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer Res (1997) 0.86
Frameshift mutations in TGFbetaRII, IGFIIR, BAX, hMSH3 and hMSH6 are absent in lung cancers. Carcinogenesis (1999) 0.86
Postoperative prognosis in patients with non-small cell lung cancer with synchronous ipsilateral intrapulmonary metastasis. Ann Thorac Surg (1997) 0.85
Immunohistochemical study of mononuclear cell infiltrates in squamous cell carcinoma of oral cavity and paranasal sinus. Oncology (1987) 0.85
Prediction of pulmonary complications after a lobectomy in patients with non-small cell lung cancer. Thorax (2001) 0.85